2I9I2016
`
`Xenoport — Horizait — FiercePha*ma
`
`<seIectanomersne I
`
`SEAI~1k,ZH
`
`WSESCIENC
`
`DO
`
`REGENERON
`SCIf.’I7C£’ lo I71€dICIl7€'
`
`
` CAN
`SIGN ME UP
`
`EMAIL ADDRESS
`
`FiercePharma
`
`NEWS TOPICS ANALYSIS FEATURES LIBRARY EVENTS JOBS MARKETPLACE
`
`wuowuseoa
`
`JOIN 150,000+ INSIDERS
`SIGN UP FOR OUR
`NEWSLETTER
`FiercePhanna is the phanna industnrs daily monitor,
`with a special focus on phamiaceutical company
`news and the market development of FDA approved
`products. Join thousands of phanna industry leaders
`who get FiercePharma via daily email. Sign up today!
`It Ixtlll
`Ill
`l|l‘|I‘lIl
`
`EMAIL ADDRESS
`
`SIGN ME UT‘
`
`THE STORY IN ACTION
`
`MAKING DRUGS
`
`cc ALTHEA | THE auwrn ID MAKE
`
`OPULAR STORIES
`
`L P
`
`MOST READ I MOST SHARED
`Doctors pounce on ‘alarmist,’ horrifying‘ Novaitis
`heart—failure ad
`
`Top exec exits as Pfizer redraws org chart for post-
`megamerger future
`NICE, in reversal, OKs Amgen's Repatha while
`snubbing Sanoti and Regeneron's Praluent
`Some top GSK investors aren't sold on a breakup-
`and they're backing CEO Witty, too
`Tdreda-Teva JV ‘could be a trendsetter as Japan
`pushes for generics: analyst
`
`Xenoport - Horizant
`November 27, 2012
`
`SHARE
`
`Email
`
`The company: XenoPort
`The drug: Horizant
`The disease: Restless leg syndrome
`Sales: $1.6 milion in 03
`
`C;
`
`When G|axoSmithKline (SGSK) signed on to partner with XenoPort
`($XNPT) on its experimental therapy for restless leg syndrome, the
`pharma giant offered up $75 million upfront and more than a half billion
`dollars in milestones. But regulators held up the approval process for three years,
`unti they were satisfied that the tumors seen it animal studies wouldn't pose a risk
`to humans. And last spring, when the FDA approval came througi, the biotech
`company was happy to leave the marketing etfort to GSK, which said it was
`gearing up 500 reps to sell the treatment
`
`TOOLS
`
`And then it all went to hell.
`
`I?comment
`
`Prim
`
`XenoPort's partnership with G|axoSmithKline on Horizant was in trouble almost
`from the start of the commercialization effort. A paltry $1.3 million in initial sales for
`the first quarter on the market triggered accusations of a breach of contract. And
`then GSK quickly pinched back with a counterclaim.
`
`Alter that, the two companies expended more effort in the legal wrangle than on
`marketing efforts. And just days ago they agreed to go their separate ways, with
`GSK signing otf on a deal to buy XenoPort shares in exchange for the right to
`wash its hands of the relationship and the therapy. And in place of making big
`revenue off of sales, GSK took a $165 million writeoff.
`
`For more:
`
`GSK, XenoPort part ways after Horizant disappointment
`Will Horizant's new use soothe tempers at XenoPort, GSK?
`GSK hits back at XenoPort in RLS drug dispute
`XenoPort rockets up alter FDA approves Horizant for RLS
`
`
`Special Report: 10 top drug launch disasters
`
`K—V Pharmaceuticals — Makena
`
`'7‘ Savient — Krystexxa
`
`|| Dendreon — Provenge
`ll Sanofi — Multaq
`litp1Iwww.fierceplamacornlspecid-reportsIxemport—lnrizat-top-10-rhig-lanch-dsasters
`
`Page 1 of 3
`
`I THE LIBRARY: MULTIMEDIA
`FierceBiotech Radio on the burning hole in
`Gilead's $253 pocket and AbbVie's future in
`
`SENJU EXHIBIT 2306 1,3
`LUPIN V. SENJU
`
`IPR2015—01099
`
`

`

`2/9/‘2016
`
`Sanofi - Zaltrap
`Human Genome Sciences -
`
`Benlysta
`
`ll
`
`x°"°p°" ‘ H°'iz‘""
`
`Xenoport — Horizant— FiercePharma
`Somaxon - Silenor
`
`hematology
`
`Astraleneca - Brilinta
`Rare Disease Therapeutics -
`A"aS°°'P
`
`‘-1 ' DECEMBER 10’ 2015
`FieIcePharma's Carly Helfand and
`FiemeB,»olech.s Damian Game
`discuss the discussion around Gilead
`Sciences‘ huge cash reserve and the many
`things the company might buy. Plus, a look
`
`back at AbbVie's blockbuster buyout of
`Phannacyclics and a consideration of how a
`certain biotech entrepreneur is bringing
`attention to an FDA loophole.
`
`MORE ITEMS
`
`LATEST COMMENTARY
`
`AstraZeneca chief chalks up milestones on his map
`to $458
`
`What's the calendar bringing biophanna next year?
`Our top 5 ideas
`The most popular FiercePhanna stories of 2015
`
`Does new scmtiny threaten pharma's specialty-
`pharrnacy strategy?
`Pfizer responds to FiercePhanna
`
`EVENTS
`
`BIO Asia lntemational Conference
`March 15-16, 2016 — Grand Hyatt, Tokyo,
`Japan — Sponsored by: BIO
`BioBasics: Biotech for the Non—Scientist
`Course
`Course |Apnl 21-22, 2016 — Boston, MA —
`Sponsored By: FierceBiotech 8- Duane Morris
`
`Drug Development Immersion Course
`Course I May 17-18, 2016 — West Windsor
`(Princeton area), NJ — Sponsored By:
`FierceBiotech
`
`MORE EVENTS
`
`
`
`NEXT
`BACK
`
`
`
`
`FEATURED JOBS
`
`> Need a job? Need to hire? Visit our jobs site.
`
`PRESS RELEASES
`
`Amplyx Phannaceuticals Expands Management Team and Increases Its
`Series B Financing to $49.2 Million
`SANOFI DELIVERED 2015 BUSINESS EPS UP 8.5‘/o ON A REPORTED
`BASIS AND STABLE AT CONSTANT EXCHANGE RATES CONSISTENT
`WITH GUIDANCE
`
`CMS will cover percutaneous LAAC therapy for Medicare beneficiaries
`consistent with the FDA label when specific conditions are met
`Sigmoid Pharma Announces Acquisition of Freund Pharmatec Ltd.
`Sientra Announces Return of All Products to U.S. Market
`More Press Releases
`
`httpj/www.fiercepharma.ccxnIspecial-reports/xenoporbhorizart—top—10-dug-lamch-disasters
`
`Page 2 of 3
`
`
`
`

`

`Page 3 of 3
`Page 3 of 3
`
`Page 3 of 3
`
`